Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001
Reappraisal of Temporary Levodopa Withdrawal ("Drug Holiday") in Parkinson's Disease
NEJM 313:724-728, Mayeux,R.,et al, 1985
Alternate Day Levodopa Therapy in Parkinsonism
Neurol 32:324-326, Koller,W.C., 1982
Complications of Chronic Levodopa Therapy; Long-term Efficacy of Drug Holiday
Neurol 31:473-476, Koller,W.C.,et al, 1981
Weekly Drug Holiday in Parkinson Disease
Neurol 31:1460-1462, Goetz,C.G.,et al, 1981
Is L-DOPA Drug Holiday Useful
Neurol 30:785-788, Direnfield,L.K.,et al, 1980
Drug Holiday & Management of Parkinson Disease
Neurol 30:1257-1261, Weiner,W.J.,et al, 1980
Drug Holidays for Patients with Parkinsonism
JAMA 242:17-21, Clark,W.A., 1979
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Deep Brain Stimulation in Early-Stage Parkinson Disease
Neurol 95:e393-e401,e431, Hacker, M.L.,et al, 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinsons Disease
NEJM 383:2501-2513,2582, Martinez-Fernandez, R.,et al, 2020
A Demure Teenager and Her Dystonic Foot
Neurol 89:e71-e75, Cullinane, P.W.,et al, 2017
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients with Advanced Parkinson Disease: A Randomized Controlled Trial
JAMA 301:63-73,104, Weaver,F.M.,et al, 2009
Overweight After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease: Long Term Follow-Up
JNNP 80:484-488, Bannier,S.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease
Neurol 68:272-276, Watts,R.L.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Improvement of Gait by Chronic, High Doses of Methylphenidate in Patients with Advanced Parkinsons Disease
JNNP 78:470-475, Devos,D.,et al, 2007
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Is DBS-STN Appropriate to Treat Severe Parkinson Disease in an Elderly Population?
Neurol 68:1345-1355, Derost,P.-P.,et al, 2007
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
A Randomized Trial of Deep-Brain Stimulation for Parkinsons Disease
NEJM 355:896-908, Deuschl,G.,et al, 2006
Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Reversal of Parkinsonism Following Liver Transplantation
Neurol 60:519, Shulman,L.J.,et al, 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Complications of Gamma Knife Surgery for Parkinson Disease
Arch Neurol 58:1995-2002,1970, Okun,M.S.,et al, 2001
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Clinical Characteristics of Pramipexole-Induced Peripheral Edema
Arch Neurol 57:729-732, Tan,E.K.&Ondo,W., 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000